# Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

> **NCT03179943** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fox Chase Cancer Center** · enrollment: 21 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Guadecitabine

## Key facts

- **NCT ID:** NCT03179943
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-11-27
- **Primary completion:** 2020-07-12
- **Final completion:** 2022-07
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-11-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03179943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03179943, "Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03179943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*